Last Updated: November 13, 2026

Chiesi Company Profile

« Back to Dashboard

What is the competitive landscape for CHIESI

CHIESI has fifteen approved drugs.

There are fifty-three US patents protecting CHIESI drugs.

Summary for Chiesi

US Patents:	53
Tradenames:	16
Ingredients:	10
NDAs:	15
Patent Litigation for Chiesi:	See patent lawsuits for Chiesi

Drugs and US Patents for Chiesi

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-003	Jul 31, 2008	AP	RX	Yes	Yes	8,455,524	⤷ Start Trial				⤷ Start Trial
Chiesi	CARDENE SR	nicardipine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020005-001	Feb 21, 1992		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Chiesi	ZYFLO CR	zileuton	TABLET, EXTENDED RELEASE;ORAL	022052-001	May 30, 2007		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Chiesi

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	CARDENE	nicardipine hydrochloride	CAPSULE;ORAL	019488-001	Dec 21, 1988	3,985,758	⤷ Start Trial
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-006	Apr 23, 2015	10,016,404	⤷ Start Trial
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-003	Dec 21, 2012	10,555,938	⤷ Start Trial
Chiesi	CLEVIPREX	clevidipine	EMULSION;INTRAVENOUS	022156-001	Aug 1, 2008	5,856,346	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for CHIESI drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	500 mg	➤ Subscribe	2016-01-29
➤ Subscribe	Injection	2.5 mg/mL, 10 mL Ampoules	➤ Subscribe	2006-12-27
➤ Subscribe	Inhalation Solution	300 mg/4 mL	➤ Subscribe	2017-08-31
➤ Subscribe	Injection	0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL	➤ Subscribe	2013-06-20

International Patents for Chiesi Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Canada	2975599	⤷ Start Trial
Moldova, Republic of	3253401	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2009140407	⤷ Start Trial
Israel	245172	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Chiesi Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1725234	132014902228079	Italy	⤷ Start Trial	PRODUCT NAME: LOMITAPIDE E OGNI SUA FORMA TERAPEUTICAMENTE EQUIVALENTE COME PROTETTA DAL BREVETTO BASE(LOJUXTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/851/001/-003, 20130805
2515855	201740046	Slovenia	⤷ Start Trial	PRODUCT NAME: COMBINATION OF GLYCOPYRRONIUM BROMIDE, FORMOTEROL OR ITS SALT AND BECLOMETASONE DIPROPIONATE; NATIONAL AUTHORISATION NUMBER: EU/1/17/1208/001-005; DATE OF NATIONAL AUTHORISATION: 20170717; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2515855	LUC00060	Luxembourg	⤷ Start Trial	PRODUCT NAME: COMBINAISON DE BROMURE DE GLYCOPYRRONIUM, FORMOTEROL OU UN SEL DE CELUI-CI ET DIPROPIONATE DE BECLOMETASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1208 20170719
2515855	1890005-0	Sweden	⤷ Start Trial	PRODUCT NAME: A COMBINATION OF GLYCOPYRRONIUM BROMIDE, FORMOTEROL OR A SALT THEREOF AND BECLOMETASONE DIPROPIONATE.; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/17/1208, 2017-07-19; DEN 2025-05-19 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD: 1590005-3,1890005-0
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Chiesi

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.